KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Mepolizumab Efficacy in COPD: Insights from Longitudinal Patterns of Blood Eosinophil Counts and Their Variability Across Three Clinical Trials.

Gerard J Criner, Henrik Watz, MeiLan K Han, Fernando J Martinez, Steven Gould, Jeff Min, Arunangshu Biswas, Stefanie Kolterer, Dave Singh

Am J Respir Crit Care Med aamag288

PMID42265988
PMCID-
DOI10.1093/ajrccm/aamag288
发表日期2026-06-10
AI 判定该论文不进入自动 KM 提取:This is a pooled analysis of three separate Phase III RCTs, not an individual trial reporting its own results. The abstract describes a post-hoc or secondary analysis of pooled data, which falls under meta-analysis or pooled analysis category.
摘要

摘要

RATIONALE: Blood eosinophil count (BEC) is a biomarker indicating type 2 (T2) inflammation in patients with chronic obstructive pulmonary disease (COPD) but can be variable. OBJECTIVES: Evaluate mepolizumab efficacy in patients with COPD with variability of BEC patterns. METHODS: Data were pooled from Phase 3, randomized, double-blind, placebo-controlled METREX (NCT02105948), METREO (NCT02105961), and MATINEE (NCT04133909) trials. Patients receiving mepolizumab 100 mg or placebo were included. These trials documented historical BEC (within 12 months before randomization) for all patients. Outcomes included annualized rates of moderate or severe exacerbations, and exacerbations requiring an emergency department (ED) visit and/or hospitalization. Outcomes were assessed in subgroups based on BEC values in the 12 months before randomization, at screening, and at baseline. MEASUREMENTS AND MAIN RESULTS: Annualized rates of moderate or severe exacerbations were reduced, or trended towards reduction, with mepolizumab versus placebo in patients with T2 inflammation characteristics, including those with BEC ≥ 300 cells/µL at any pre-randomization timepoint (21% reduction), persistently elevated BECs (12-27% reduction), and variable BECs over time (22-36% reduction). Across various subgroups with elevated BEC, starting from ≥ 150 cells/µL, mepolizumab reduced exacerbations requiring ED visit and/or hospitalization. Patients with persistently low BEC (<150 cells/µL) experienced no benefit with mepolizumab. CONCLUSIONS: Mepolizumab improved exacerbation-related outcomes in patients with COPD and T2 inflammation, characterized by both consistently and intermittently elevated BEC. Persistent BEC elevation is not required to identify treatable eosinophilic phenotypes in COPD.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。